Autism Screening with Advanced Technology: Insights from the START App

By Melike Belenli Gümüş

August 27, 2024

Introduction

Autism, a prevalent neurodevelopmental condition affecting approximately 1% globally, poses challenges in timely diagnosis, particularly in countries like India with around 5 million affected families. Limited awareness and scarce specialist resources hinder early interventions, emphasising the critical need for accessible screening tools. Addressing this, autism screening with advanced technology has seen significant advancements in recent years. An online platform, the START app is a prime example of this progress. It allows non-specialists to assess autism risk in low-resource settings, aiming to bridge the detection gap efficiently. Dubey et al. studied the app’s feasibility, accuracy, and community involvement. By understanding these aspects, we can appreciate the potential of technology in early autism detection and highlight its value in healthcare.

Feasibility and Acceptability

Researchers evaluated the START app’s feasibility through interviews with non-specialist health workers and caregivers in Delhi, India. The app was tested in home settings, ensuring real-world applicability. Non-specialist health workers conducted the interviews in Hindi.  This comprehensive approach ensured that the app could function effectively in diverse settings.

Caregivers appreciated the ease of use and the detailed feedback provided. Non-specialist health workers found the training manageable and the app user-friendly. This positive feedback indicated the app’s acceptability and potential for widespread adoption.

The app’s feasibility and acceptability translate into potential cost savings for healthcare systems. By enabling early detection and intervention, the app can reduce the long-term costs associated with untreated autism. This proactive approach aligns with value-based healthcare principles, aiming to improve patient outcomes while managing costs.

Accuracy in Classification

Researchers rigorously tested the START app’s accuracy in classifying participants, as shown in Figure 1, using machine learning methods like XGBoost, logistic regression, and support vector machines, ensuring robust results. The app effectively distinguished between typically developing children, those with autism spectrum conditions, and those with intellectual disabilities. This accuracy is vital for not only early intervention and tailored support, but also for efficient resource allocation. By identifying children needing specific interventions, healthcare providers can allocate resources more effectively, improving health outcomes and optimising healthcare funds.

Figure 1: Mean classification accuracies of the feature vectors taken from the eight START tasks. The figure also represents the most accurate classification achieved by a combination of these features.

Community Involvement

Community involvement was a cornerstone of the START app’s development. An autistic researcher participated in regular discussions during the analysis of pilot data. This inclusion ensured that the app was designed with the needs of the autism community in mind.

A dedicated dissemination event was organised for autism community stakeholders in India. Local clinicians, researchers, policymakers, and government organisation members attended. The lead researchers demonstrated the task battery and presented preliminary results in accessible language. This engagement fostered a sense of ownership and trust within the community.

Assessment Procedure

For the assessment of the START app, two high-school graduates were trained as non-specialist health workers through a four-day program, including classroom sessions and supervised field training. Psychology postgraduate research assistants oversaw the data collection, ensuring adherence to research procedures and supporting the health workers, thus maintaining data integrity.

The assessment tools included the Developmental Profile 3 (DP-3) and the INCLEN Diagnostic Tool for Autism Spectrum Disorder (INDT-ASD), administered by the research assistants for accuracy and reliability. This structured procedure ensures high-quality data, essential for evaluating the app’s effectiveness and cost-effectiveness, supporting evidence-based decision-making in value-based healthcare.

Conclusion

The START app represents a significant advancement in autism screening technology. Its feasibility and acceptability in diverse settings, combined with its accuracy in classification, make it a valuable tool. Community involvement in its development and assessment ensures it meets the needs of those it aims to serve. The app aligns with value-based healthcare principles by improving outcomes and managing costs. Furthermore, accurate classification and early intervention can lead to significant cost savings and better resource allocation. As technology continues to evolve, tools like the START app will play a crucial role in early autism detection and intervention.

Reference url

Recent Posts

bioelectronic medicine innovations
     

Bioelectronic Medicine Innovations: Advancing Non-Invasive Neuromodulation Strategies

🌟 *Ready to explore the future of medicine?*
The new frontier of bioelectronic innovations is reshaping how we approach health. With advancements in non-invasive closed-loop systems, we can personalize treatments and improve patient outcomes without the need for surgical procedures. Discover the groundbreaking potential of autonomic neuromodulation in tackling chronic health conditions in our latest article.

#SyenzaNews #HealthcareInnovation #DigitalHealth #PrecisionMedicine

cervical cancer burden
       

Cervical Cancer Burden: Global Trends and Future Projections

💡 Did you know cervical cancer accounted for 662,044 new cases globally in 2022?

This article jumps into the sobering statistics of cervical cancer, highlighting the stark disparities in incidence and mortality rates tied to human development indexes.

With projections suggesting a dramatic rise in cases by 2050, the urgency for enhanced preventive measures has never been clearer.

Read more about the crucial steps we need to take to combat this growing health issue.

#SyenzaNews #globalhealth #HealthEconomics

datopotamab deruxtecan approval
   

FDA Grants Datopotamab Deruxtecan Approval for HR-Positive Breast Cancer Treatment

💡 *What does the FDA’s latest approval mean for patients with advanced breast cancer?*
Datopotamab deruxtecan (Datroway) has just been approved for treating unresectable or metastatic HR-positive, HER2-negative breast cancer, offering new hope for patients who have already undergone multiple therapies. This breakthrough, stemming from the TROPION-Breast01 trial, showcases significant improvements in progression-free survival rates—a vital advancement in cancer care.

Curious about the implications of this treatment for both healthcare providers and patients? Dive into the full article to learn more!

#SyenzaNews #oncology #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.